JDQ443

JDQ443 is a small-molecule drug developed by Novartis Pharmaceuticals. Its target is KRAS (the sponsor names KRAS G12C). ClinicalTrials.gov describes the intervention as: JDQ443 per os (PO) 200 mg twice a day continuously. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05132075 (Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer), in non-small-cell lung cancer and colorectal cancer. The largest, NCT04699188, plans to enrol 344 participants (actual) with primary completion expected 2027-01-25. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.